Tesamorelin: Frequently Asked Questions
The 10 most common questions about Tesamorelin therapy, answered in plain language.
1.What is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of human GHRH with an added trans-3-hexenoic acid modification at the N-terminus that improves stability and potency. It was developed by Theratechnologies and is sold under the brand name Egrifta. Tesamorelin is the only GHRH analog that has received full FDA approval, specifically for the reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients with lipodystrophy. It stimulates the pituitary gland to produce and release growth hormone in a pulsatile, physiological manner.
2.What is Tesamorelin commonly used for?
Tesamorelin is commonly sought for targeted visceral fat reduction and body composition improvement. Its FDA-approved indication is for HIV-associated lipodystrophy, but it is widely used off-label for general visceral fat reduction in non-HIV populations. Patients often report significant reductions in waist circumference and visceral adipose tissue as measured by imaging. It has been associated with improvements in triglycerides and other cardiometabolic markers. Research also suggests Tesamorelin may have cognitive benefits, with a study showing improved verbal memory and executive function in older adults at risk for Alzheimer's disease.
3.Is Tesamorelin safe?
Tesamorelin has undergone rigorous FDA review and approval, giving it one of the strongest safety pedigrees among peptides used in clinical practice. Clinical trials demonstrated it is generally well-tolerated, with the most common adverse events being injection site reactions and peripheral edema. Because it stimulates endogenous growth hormone production, the natural feedback mechanisms remain intact, limiting the risk of supraphysiological GH levels. However, it does raise IGF-1 levels, and monitoring is recommended. It should be used with caution in patients with pre-existing malignancies due to the growth-promoting effects of elevated GH/IGF-1.
Have more questions? Get matched with a provider who specializes in Tesamorelin →
4.What are the potential side effects of Tesamorelin?
The most common side effects in clinical trials were injection site reactions (erythema, pruritus, pain, and irritation) and peripheral edema, each occurring in approximately 5-10% of patients. Joint pain (arthralgia), muscle pain (myalgia), and paresthesias in the extremities have also been reported, all consistent with growth hormone elevation. Some patients experience elevated fasting glucose, so glucose monitoring is important, particularly for those with pre-existing insulin resistance. Nausea and hypersensitivity reactions have been reported rarely. Discontinuation of Tesamorelin leads to reaccumulation of visceral fat, suggesting ongoing use is needed to maintain benefits.
5.How is Tesamorelin administered?
Tesamorelin is administered via daily subcutaneous injection in the abdominal area. The FDA-approved dose is 2 mg injected once daily, and the branded product (Egrifta/Egrifta SV) comes with a mixing device for reconstitution. Compounded versions are also available and reconstituted with bacteriostatic water using standard insulin syringes. Injections are typically given in the morning or evening, and while specific meal timing is not as critical as with shorter-acting GHRH analogs, some practitioners advise against injecting immediately after a high-carbohydrate meal. Rotation of injection sites within the abdominal area is recommended.
6.How long does Tesamorelin take to work?
Measurable reductions in visceral adipose tissue are typically observed within eight to twelve weeks, as demonstrated in clinical trials that used CT scans to quantify visceral fat. Reductions in waist circumference may be noticeable to the patient somewhat earlier, often within four to six weeks. The Phase III LIPO trials showed an average 15% reduction in visceral adipose tissue after 26 weeks. Improvements in triglycerides and IGF-1 levels are generally detectable on blood work within four to eight weeks. For the potential cognitive benefits observed in research, longer-term use of six months or more appears necessary.
Have more questions? Get matched with a provider who specializes in Tesamorelin →
7.How much does Tesamorelin cost?
Branded Tesamorelin (Egrifta SV) is one of the most expensive peptide therapies, with a list price of approximately $1,000 to $1,500 per month without insurance. Insurance coverage is typically available only for the FDA-approved indication of HIV-associated lipodystrophy. Compounded Tesamorelin is significantly more affordable, typically costing $200 to $500 per month depending on the pharmacy and dose. Some clinics offer it as part of body composition programs for $400 to $800 per month including monitoring. The branded-to-compounded price differential is substantial, making the compounded route far more common for off-label use.
8.Do I need a prescription for Tesamorelin?
Yes, Tesamorelin requires a prescription from a licensed healthcare provider. For the branded product, the prescription is filled through specialty pharmacies, and prior authorization from insurance is typically required. For compounded Tesamorelin, a prescription is directed to a compounding pharmacy. The prescribing provider should conduct baseline labs including IGF-1, fasting glucose, HbA1c, and a lipid panel. Imaging such as DEXA or CT for visceral fat measurement may be ordered for objective baseline assessment. Follow-up labs at 6-12 week intervals are standard to monitor IGF-1 levels and metabolic markers.
9.Can Tesamorelin be combined with other peptides?
Tesamorelin is sometimes combined with Ipamorelin for a synergistic GHRH plus ghrelin-mimetic approach to growth hormone optimization, similar to the CJC-1295/Ipamorelin combination but with the advantage of Tesamorelin's FDA-approved profile. For enhanced fat loss, it can be paired with AOD-9604 or Semaglutide, targeting different mechanisms of body composition improvement. BPC-157 may be added for gut health or tissue repair support. It should generally not be combined with other GHRH analogs like CJC-1295 or Sermorelin, as they compete for the same receptor. All combinations should be managed by an experienced provider with regular monitoring.
Have more questions? Get matched with a provider who specializes in Tesamorelin →
10.Who is a good candidate for Tesamorelin?
The strongest evidence base is for HIV-infected individuals with lipodystrophy, for whom it is FDA-approved. Beyond this, adults with elevated visceral adipose tissue, particularly those with metabolic syndrome, elevated triglycerides, or increased cardiovascular risk related to abdominal obesity, are common candidates for off-label use. Individuals who have not achieved adequate visceral fat reduction through diet, exercise, and other interventions may benefit from Tesamorelin. It is contraindicated in pregnancy, in individuals with disruption of the hypothalamic-pituitary axis from conditions like pituitary tumors, and in those with active malignancy. A thorough metabolic and endocrine evaluation is important before starting.
Still have questions about Tesamorelin?
A qualified provider can give you personalized answers based on your health history and goals.
Get Matched With a Tesamorelin ProviderLearn More About Tesamorelin
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Peptide therapies should only be administered by licensed healthcare providers. Always consult with a qualified healthcare professional before starting any new treatment. PeptideLeads is a marketing agency and does not provide medical services.